(R)-Lisofylline 是溶血磷脂酸酰基转移酶的抑制剂 (IC50 = 0.6 μM)。 (R)-Lisofylline 可中断 IL-12 信号介导的 STAT4 激活，可用于治疗 1 型糖尿病和自身免疫性疾病的研究。

(R)-Lisofylline is an inhibitor of lysophosphatidic acid acyltransferase (IC50 = 0.6 μM). (R)-Lisofylline interrupts IL-12 signaling-mediated STAT4 activation and can be used in studies about the treatment of type 1 diabetes and autoimmune disorders.

(R)-Lisofylline blocks IL-12-driven T cell proliferation and Th1 differentiation yet has no effect on IL-12 secretion[1].

In NOD mice, (R)-Lisofylline prevents β cell dysfunction by inhibition of STAT4 phosphorylation and ameliorates experimental allergic encephalomyelitis. (R)-Lisofylline reduces the impairment of insulin secretion induced by IL-1β in cultured rat islet cells, suppresses IFN-γ production, the onset of diabetes, and macrophage infiltration into islets. (R)-Lisofylline improves insulin response and lowers glucose levels in Streptozotocin-treated rats after the oral glucose tolerance test. In rats given IL-1 intratracheally (R)-Lisofylline pretreatment reduces lung leak but does not decrease neutrophil accumulation in lungs. (R)-Lisofylline improves survival in mice injected with a lethal dose of LPS and ameliorates sepsis-induced lung injury in minipigs[2].

100324-81-0

C13H20N4O3

280.32

(< 1 mg/ml refers to the product slightly soluble or insoluble )
Powder: -20°C for 3 years
In solvent: -80°C for 2 years